ORBIMED ADVISORS LLC 13D and 13G filings for Prelude Therapeutics Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-24 4:47 pm Purchase | 2023-05-22 | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 15,716,642 28.600% | 869,565 (+5.86%) | Filing |
| 2021-01-13 5:34 pm Purchase | 2021-01-11 | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 14,847,077 31.900% | 41,700 (+0.28%) | Filing |
| 2020-10-05 5:17 pm Purchase | 2020-09-25 | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 14,805,377 33.900% | 14,805,377 (New Position) | Filing |